68Ga-citrate PET/MR Imaging for Glioma
| Status: | Recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 11/9/2017 |
| Start Date: | May 31, 2016 |
| End Date: | January 1, 2020 |
| Contact: | Kenneth Gao, BS |
| Email: | kenneth.gao@ucsf.edu |
| Phone: | 415-353-9437 |
68Ga-citrate PET/MR Imaging for the Evaluation of Glioma in Adults
This is a prospective, Phase 2, single center, open-label study in adult patients with
presumed WHO grade 3 or 4 glioma who will be undergoing surgical resection as standard of
care. In some cases, patients will have had biopsy. Study participants will undergo
68Ga-citrate PET/MR prior to surgery.
presumed WHO grade 3 or 4 glioma who will be undergoing surgical resection as standard of
care. In some cases, patients will have had biopsy. Study participants will undergo
68Ga-citrate PET/MR prior to surgery.
Inclusion Criteria:
- WHO grade 3 or 4 glioma planning to undergo surgery
- Age >= 18 years
- Karnofsky performance status of >= 60
- Ability to understand a written informed consent document, and the willingness to sign
it
Cohort A - 20 subjects
- Positive for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy Cohort
B - 20 subjects
- Negative for PTEN deletion, confirmed by immunohistochemistry of tissue biopsy
Exclusion Criteria:
- Contraindications to PET imaging (e.g. pregnant or breast-feeding woman)
- Contraindications to MR imaging (e.g. pacemakers, metallic implants, etc.)
We found this trial at
1
site
San Francisco, California 94143
Principal Investigator: Susan Chang, MD
Phone: 415-353-9437
Click here to add this to my saved trials
